How CGM technology works

A continuous glucose monitor is, at its core, a miniaturized electrochemical biosensor combined with wireless communication technology. It works by detecting a chemical reaction between glucose molecules and an enzyme on the sensor tip, converting that reaction into an electrical signal, and transmitting that signal to a display device.

The entire process — from glucose molecule contacting the sensor to a reading appearing on your phone — happens in seconds, and repeats every one to five minutes, 24 hours a day, for the lifetime of the sensor.

🧪

Layer 1 — Biochemistry

Glucose in interstitial fluid reacts with glucose oxidase enzyme on the sensor filament. This enzymatic reaction produces hydrogen peroxide proportional to glucose concentration — the chemical signal that begins the measurement chain.

Layer 2 — Electrochemistry

The hydrogen peroxide is oxidized at a platinum electrode, generating a tiny electrical current. This amperometric current — measured in nanoamperes — is directly proportional to the glucose concentration in the surrounding fluid.

🔢

Layer 3 — Signal processing

Raw electrical signals are noisy and require calibration. Algorithms in the transmitter correct for sensor drift, temperature variation, tissue response, and other confounding factors to convert the raw current into an accurate glucose value in mg/dL or mmol/L.

📡

Layer 4 — Wireless transmission

The processed glucose value, along with trend and signal quality data, is transmitted via Bluetooth Low Energy to a receiver, smartphone, or smartwatch. Modern CGM systems transmit every one to five minutes and maintain connectivity at ranges up to 6–9 meters.

The electrochemistry of glucose sensing

The core of every CGM sensor is an amperometric enzyme electrode — a technology that has been refined over decades from laboratory instruments into something small enough to wear under the skin for two weeks.

The glucose oxidase reaction

The enzyme glucose oxidase (GOx) catalyzes a specific chemical reaction: it converts glucose and oxygen into gluconic acid and hydrogen peroxide. This reaction is highly specific to glucose — it will not respond to other sugars or molecules in interstitial fluid, which is essential for accuracy.

The reaction can be written as: Glucose + O₂ → Gluconic acid + H₂O₂

The hydrogen peroxide produced is then oxidized at a platinum working electrode, releasing two electrons per molecule. This generates a measurable electrical current. Since the current is proportional to the hydrogen peroxide concentration — which is proportional to the glucose concentration — measuring the current gives a glucose reading.

The three-electrode system

CGM sensors use a three-electrode electrochemical cell: a working electrode (where glucose oxidation occurs), a reference electrode (which provides a stable voltage reference), and a counter electrode (which completes the electrical circuit). This three-electrode design is more stable and accurate than a simpler two-electrode system, particularly over multi-day sensor wear periods.

Membrane layers and selectivity

The sensor filament is coated with multiple membrane layers, each serving a specific function. An outer biocompatible membrane controls glucose flux into the sensor, preventing enzyme saturation at high glucose levels. An interference-rejecting membrane blocks electroactive molecules (such as acetaminophen and uric acid) that could falsely elevate readings. The enzyme layer contains immobilized glucose oxidase. An inner inner membrane controls access to the electrode surface.

The design and composition of these membranes is where much of the differentiation between CGM manufacturers lies — and where the most significant engineering has occurred over successive product generations.

Why oxygen matters

The glucose oxidase reaction requires oxygen as a co-substrate. In tissue, oxygen concentration is lower and more variable than in blood, which can affect sensor accuracy. Modern CGM sensors use membrane engineering and algorithms to compensate for oxygen variability — but it remains a fundamental constraint of enzyme-based glucose sensing.

The three components of a CGM system

01
The sensor
A flexible electrochemical filament typically 5–7mm long and 0.3–0.4mm in diameter, inserted into subcutaneous tissue. Contains the enzyme, electrode system, and membrane layers. Worn for 10–15 days before replacement.
Key specs Length: 5–7mm · Diameter: ~0.3mm · Wear: 10–15 days · Site: abdomen, upper arm
02
The transmitter
Sits on top of the sensor patch and reads the electrical signal from the sensor 288 times per day. Contains analog-to-digital conversion, calibration algorithms, battery, and Bluetooth radio. Either disposable (integrated) or reusable.
Key specs Reading interval: 5 min · Bluetooth range: 6–9m · Battery: 10–15 days (disposable) or rechargeable
03
The display
Receives Bluetooth data from the transmitter and displays glucose value, trend arrow, and history graph. May be a dedicated receiver, smartphone app, or smartwatch. Stores data and provides alerts, pattern analysis, and sharing capabilities.
Key specs Update frequency: every 5 min · Alert types: high, low, rate of change · Sharing: real-time via cloud

Generations of CGM technology

CGM technology has advanced through several distinct generations, each bringing meaningful improvements in accuracy, wear time, ease of use, and accessibility.

Generation Calibration Wear time MARD Key advance
1st gen (pre-2015) 2–4x daily 3–7 days 14–18% Proof of concept — continuous monitoring possible
2nd gen (2015–2018) 2x daily 7–10 days 10–13% Improved accuracy, longer wear, smartphone integration
3rd gen (2018–2022) Factory calibrated 10–14 days 8–10% No finger-stick calibration required, Dexcom G6, Libre 2
Current gen (2022–) Factory calibrated 14–15 days 7–9% OTC availability, smaller form factor, direct-to-watch, Dexcom G7/Stelo, Libre 3
Next gen (emerging) Factory calibrated 15–30+ days <7% target Implantable sensors, non-enzymatic sensing, multi-analyte measurement

The shift to factory calibration — removing the requirement for twice-daily finger-stick calibrations — was the most transformative usability advance in CGM history. It eliminated a major barrier to adoption and enabled CGM use in situations (such as overnight wear) where stopping to calibrate was impractical.

Understanding CGM accuracy and MARD

CGM accuracy is measured using Mean Absolute Relative Difference (MARD) — the average percentage difference between CGM readings and simultaneous laboratory blood glucose measurements. A MARD of 9% means the CGM reading is, on average, within 9% of the true blood glucose value.

Dexcom G7 8.2%
Abbott FreeStyle Libre 3 7.8%
Medtronic Guardian 4 8.8%
Finger-stick meter (reference) ~5%
What MARD means in practice

A MARD of 8% at a blood glucose of 100 mg/dL means the CGM reading may be anywhere from 92–108 mg/dL. At 200 mg/dL, the range widens to 184–216 mg/dL. For most clinical decisions this is acceptably accurate, but it is why finger-stick verification remains important for critical treatment decisions.

Factors that improve accuracy

Factory calibration algorithms trained on large datasets · Proper sensor insertion site and technique · Avoiding compression of the sensor (sleeping on it) · Stable glucose levels (less lag effect) · Adequate hydration · Sensor in the middle of its wear period

Factors that reduce accuracy

Rapidly changing glucose (meals, exercise, hypoglycemia) · First 24 hours of sensor wear · Sensor compression during sleep · High-dose acetaminophen or other interfering medications · Extreme temperatures · End of sensor wear period · Improper insertion site or technique

The interstitial lag — why CGM lags blood glucose

CGM sensors measure glucose in interstitial fluid — the fluid that surrounds cells in subcutaneous tissue — not glucose in blood directly. Glucose moves from blood capillaries into interstitial fluid by diffusion, a process that takes time.

This physiological delay means that during periods of rapidly changing blood glucose, the CGM reading lags behind the true blood glucose by approximately 5–15 minutes. When blood glucose is rising quickly after a meal, CGM will underestimate the true peak. When glucose is falling rapidly during hypoglycemia, CGM may underestimate the severity.

How trend arrows compensate for lag

Trend arrows on CGM displays indicate the direction and rate of glucose change, helping users anticipate where glucose is heading rather than just where it appears to be. An arrow showing rapidly falling glucose is a warning to act even if the displayed number is not yet in the low range. Understanding trend arrows is essential for safe CGM use, particularly for insulin-using patients.

Trend arrow Meaning Rate of change
↑↑ Double up Rising rapidly >3 mg/dL per minute
↑ Single up Rising 2–3 mg/dL per minute
↗ Angled up Rising slowly 1–2 mg/dL per minute
→ Flat Stable <1 mg/dL per minute
↘ Angled down Falling slowly 1–2 mg/dL per minute
↓ Single down Falling 2–3 mg/dL per minute
↓↓ Double down Falling rapidly >3 mg/dL per minute
Clinical importance

How to respond to trend arrows — particularly for insulin dosing decisions — should be determined in consultation with your healthcare provider. Many providers use published trend arrow adjustment guidelines, but these must be individualized. Never adjust insulin doses based on CGM trend arrows without guidance from your diabetes care team.

The future of CGM technology

CGM technology is advancing rapidly across several dimensions — longer wear, higher accuracy, non-invasive sensing, and measurement of additional analytes beyond glucose.

In development 🔬
Non-enzymatic sensors
Current sensors rely on glucose oxidase, which degrades over time and limits wear duration. Non-enzymatic sensing approaches using direct electrochemical oxidation or other detection mechanisms could enable much longer wear periods — potentially months — without enzyme degradation.
Clinical trials 💉
Implantable long-term sensors
Senseonics' Eversense is the only currently approved implantable CGM, lasting 6 months. Multiple companies are developing longer-duration implantable sensors that would eliminate the need for frequent sensor changes — a significant advantage for patients with intensive monitoring needs.
Research phase 📡
Non-invasive CGM
The holy grail of glucose monitoring — measuring glucose without penetrating the skin. Approaches using near-infrared spectroscopy, Raman spectroscopy, and photoacoustic sensing have been in development for decades. No non-invasive CGM has yet achieved the accuracy required for clinical use, but research continues.
Emerging 🧬
Multi-analyte sensors
Beyond glucose, future sensors may simultaneously measure lactate (for exercise monitoring), ketones (for diabetic ketoacidosis prevention), alcohol, or other metabolites. Abbott and others have announced research programs targeting multi-analyte wearable biosensors that would provide a richer metabolic picture than glucose alone.

Frequently asked questions

Why can't CGM measure blood glucose directly?
Measuring blood glucose directly would require the sensor to be in contact with blood, which creates significant safety risks (clotting, infection) and is not practical for a wearable device worn for 10–15 days. Interstitial fluid glucose is an excellent proxy for blood glucose during stable conditions, and the lag is manageable with trend arrow technology. Some research groups are developing intravascular CGM for ICU use, but these are not applicable to wearable consumer devices.
Why do CGM sensors only last 10–15 days?
Several factors limit sensor lifetime. The glucose oxidase enzyme degrades over time, reducing the electrochemical signal. The body's foreign body response encapsulates the sensor in fibrous tissue, restricting glucose access to the sensor surface. The adhesive patch also degrades with exposure to sweat and activity. Extending sensor life requires either more stable enzyme formulations, different sensing chemistries, or sensor designs that tolerate encapsulation — all active areas of development.
Does CGM technology work differently for Type 1 vs Type 2 diabetes?
The sensor technology is identical regardless of the user's diagnosis. The difference lies in how the data is used. People with Type 1 diabetes typically use CGM for intensive insulin management, closed-loop systems (artificial pancreas), and hypoglycemia prevention. People with Type 2 diabetes, particularly those not using insulin, may use CGM primarily for behavioral feedback — understanding food responses and motivating lifestyle changes. The clinical algorithms for acting on CGM data differ by treatment regimen.
Can smartwatches measure blood glucose?
As of 2026, no smartwatch can accurately measure blood glucose non-invasively. Despite claims from various manufacturers and numerous false starts, no device using optical sensing through the wrist has achieved clinically acceptable accuracy. Apple, Samsung, and others have active research programs in this area. The fundamental challenge is that optical signals from the wrist are dominated by blood flow and tissue characteristics that make isolating glucose signal extremely difficult. CGM data can be displayed on smartwatches via Bluetooth from a separate sensor — but the measurement is not coming from the watch itself.